Trial Profile
A Randomized, Double-Blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Benralizumab (Anti-IL5RA) in Subjects With Eosinophilic Gastritis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 21 Jun 2023
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Eosinophilic gastroenteritis
- Focus Therapeutic Use
- Acronyms BEGS
- 16 Jun 2023 According to an AstraZeneca media release, Co-authors also included Vidhya Kunnathur, MD, from the University of Cincinnati College of Medicine, and Amy Klion, MD, with the National Institute of Allergy and Infectious Disease (NIAID).
- 16 Jun 2023 According to an AstraZeneca media release, the co-authors for this study included first author Kara Kliewer, PhD, Cristin Murray-Petzold, BS, Margaret Collins, MD, Juan Abonia, MD, Scott Bolton, MD, Lauren DiTommaso, BS, Lisa Martin, MD, Xue Zhang, MD, Vincent Mukkada, MD, Philip Putnam, MD, Erinn Kellner, MD, Ashley Devonshire, MD, Justin Schwartz, MD, Chen Rosenberg, MD, John Lyles, MD, and Tetsuo Shoda, MD, from Cincinnati Children's.
- 16 Jun 2023 Results presented in an AstraZeneca media release.